SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Open Angle Glaucoma
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Trial Timeline
Nov 9, 2023 → Feb 22, 2024
NCT ID
NCT06144918About SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, Placebo
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, Placebo is a phase 2 stage product being developed by Skye Bioscience for Primary Open Angle Glaucoma. The current trial status is completed. This product is registered under clinical trial identifier NCT06144918. Target conditions include Primary Open Angle Glaucoma, Ocular Hypertension.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06144918 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Open Angle Glaucoma